WAVE Life Sciences Ltd

In a Stage 4 decline, WVE remains under sustained seller control with price below all key EMAs and forming sequential lower highs and lower lows. Despite extreme oversold readings and a bearish exhaustion signal, no stable base has formed, and rallies continue to stall on muted volume. The medium-term bias is bearish, and sellers should defer new execution until rallies into resistance rather than selling into diminishing downside momentum.

• ↑WVE-007 achieved placebo-adjusted 4% total fat and 9.2% visceral reduction at 240 mg dose over three months.
• ↑Proprietary RNAi/editing technology targets inhibin E, preserving lean mass versus GLP-1 therapies.
• ↓Q2 2026 net loss rose to $69.4 M from $50.5 M YoY, with R&D up to $51.3 M.